On Monday-Tuesday 10-11 June 2024, the consortium is gathering for its last consortium meeting in Rostock, Germany, for its M42 consortium meeting, where partners will assess the overall status of the project and the progress made in its last 6 months of activity (M36-M42), based on the agreements reached at the previous consortium meeting in Vienna. The meeting will be hosted at the Institut für ImplantatTechnologie und Biomaterialien e.V. (IIB).
On the first day of the meeting, the consortium will jointly analyse the progress status of the work made in the last months of the project, particularly in pursuit of the recommendations received by the European Commission’s reviewers after the Second Periodic Review (28 February 2024). An overview of the most important sessions is below.
- Project overview: follow up on the activities completed.
- Clinical data acquisition and processing (WP5-6): extraction of functional and anatomic data, generation of synthetic geometries.
- Virtual research environment (VRE) implementation and interoperability (WP3): finalisation of the VRE and its user interfaces, including interoperability of its three components, the Virtual cohort generator, the VRE Drive and the R-statistical environment for in-silico trials.
- Definition of standard operating procedures (WP4): finalisation of the remaining standard operating procedures, presentation of the final SOP collection, and interaction with regulatory and notified bodies.
- Quantification of healthcare, industry and socioeconomic effects (WP10): impact assessment on healthcare, industry and society based on in-silico trial results, literature analysis and stakeholder engagement.
- Engagement, communication, dissemination and exploitation (WP2): final publication and dissemination event planning, including the cardiovascular modelling session at the VPH 2024 conference, exploitation of the VRE and individual results.
Day 2
The second day of the meeting will focus on joint sessions covering virtual cohort creation and validation, virtual device implantation, simulation of device effects, virtual device modelling and simulation of in silico studies.
- Virtual cohort generation and validation (WP7): refinement and integration of the final version of the Virtual Cohort Generators (VCG) in the VRE, cross-validation of the VCGs based on independent cohort data (InSilicoWorld project, others).
- Virtual device implantation and device effect simulation (WP8-9): mapping of engineering metrics with clinical outcomes, conduction of the in-silico clinical trials for TAVI and PAPS and discussion of results.
- Coordination and management (WP1): preparation of the Third Periodic Report and Final Report, and of the Third Periodic Review.